伊莱克特拉治疗
ETRA
8.75
0.00
0.00%
伊莱克特拉治疗
US · ETRA
#3672 按市值排名
上市于 2026
8.75
0.00
0.00%
实时 - 追踪5344个代码 - 心跳于7秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了7家。
- 机构持股总比例上升了51.0个百分点。
机构持股
- 机构持股比例
- 50.98% +50.98pp
- 机构数量
- 7 +7
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近14个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund32.30%
Hedge Fund8.70%
Private Company6.05%
Public Company3.92%
Individual/Insider1.37%
Other47.65%
主要股东 截至 2026-09-25
OrbiMed Advisors LLC
10.97% · 6.89M 股
Westlake Village BioPartners
10.11% · 6.35M 股
Redmile Group, LLC
8.70% · 5.46M 股
EQT Life Sciences
6.05% · 3.80M 股
Lsp 7 Cooperatief U.A.
6.05% · 3.80M 股
New Leaf Venture Partners, LLC
5.18% · 3.25M 股
Sanofi
3.92% · 2.46M 股
Quehuong Dong
0.73% · 455.48K 股
Nancy Stagliano
0.41% · 255.64K 股
Graham Parry
0.14% · 85.50K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪21份申报 · 6次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| OrbiMed Advisors LLC | -- | 10.97% |
| Westlake Village BioPartners | -- | 10.11% |
| Quehuong Dong | Chief Executive Officer | 0.73% |
| Nancy Stagliano | Independent Chairperson | 0.41% |
| Graham Parry | Chief Scientific Officer | 0.14% |
| Gary Koe | Chief Technology Officer | 0.10% |
| Carl Gordon | Independent Director | -- |
| Matthew Fust | Independent Director | -- |
| David Tucker | Former Officer | -- |
| Kim-Hien Dao | Chief Medical Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-20 | OrbiMed Advisors LLC | -- | Private Acquisition | +1,333,333 | $15.00 |
| 2026-09-20 | OrbiMed Advisors LLC | -- | Derivative Exercise and Retained | +5,551,837 | -- |
| 2026-09-20 | Nancy Stagliano | Independent Chairperson | Derivative Exercise and Retained | +255,635 | -- |
| 2026-09-20 | Graham Parry | Chief Scientific Officer | Derivative Exercise and Retained | +85,504 | -- |
| 2026-09-20 | Quehuong Dong | Chief Executive Officer | Derivative Exercise and Retained | +455,484 | -- |
| 2026-09-20 | Westlake Village BioPartners | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-09-20 | Gary Koe | Chief Technology Officer | Derivative Exercise and Retained | +63,656 | -- |
| 2026-09-17 | Carl Gordon | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Matthew Fust | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | David Tucker | Former Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Nancy Stagliano | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Graham Parry | Chief Scientific Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Quehuong Dong | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Kim-Hien Dao | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-17 | Gary Koe | Chief Technology Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
伊莱克特拉治疗 讨论区 0 条评论